<DOC>
	<DOCNO>NCT02336386</DOCNO>
	<brief_summary>The purpose study determine whether Cyclophosphamide , Liposome doxorubicin Dexamethasoneï¼ˆCDD ) Plus Bortezomib might effective extramedullary plasmacytoma .</brief_summary>
	<brief_title>CDD Plus Bortezomib CDDin Relapsed Refractory Multiple Myeloma With Extramedullary Plasmacytoma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Male female patient 18 80 Biopsyproven EMP relapse refractory Myeloma disease . Patients may proteasome inhibitorexposed naive , refractory proteasome inhibitor therapy Disease require treatment Measurable disease M protein Objective measurable EMP Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Meet clinical laboratory criterion specify protocol Voluntary write consent Female patient lactate , breastfeed pregnant Evidence current uncontrolled cardiovascular condition specify study protocol Requirement concomitant chemotherapy , immunotherapy , radiotherapy , would consider treatment EMP . Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Ongoing active infection , know HIV positive , active hepatitis B C infection Psychiatric illness/social situation would limit compliance study requirement Known allergy study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Bortezomib</keyword>
</DOC>